Arkolith/Insider Trading/TERN/Form 4

Burroughs Amy L.

Chief Executive Officer, DirectorTerns Pharmaceuticals, Inc. (TERN) · full profile →Form 4 · filed Mar 17, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$681K
Net Open-Market Flow
-$681K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 16, 2026Sell(S)3K$47.30$131K289K
Mar 16, 2026Option exercise(M)15K$4.64$68K304K
Mar 16, 2026Sell(S)12K$46.57$550K292K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 16, 2026Option exercise(M)15K—$0956K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001872564-26-000008) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML